Chong Kun Dang Pharmaceutical (185750) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Chong Kun Dang Pharmaceutical KRW 100,003, price KRW 64,900, upside +54.1%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Chong Kun Dang Pharmaceutical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally.
Show more
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Stock analysis
Chong Kun Dang Pharmaceutical (185750) currently trades at 64,900 KRW, while our model-based Fair Value estimate is 100,003 KRW, implying the stock looks roughly 35.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 115,734 KRW per share, and 8 of the 14 models we run sit above the 64,900 KRW price.
Bear case: the Earnings-Based group reads lowest at 41,354 KRW, and 6 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: 75,002 KRW (bear) to 125,004 KRW (bull), the price of 64,900 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Chong Kun Dang Pharmaceutical reported revenue of 1.7T KRW in FY2025 versus 1.3T KRW in FY2021, a compound +5.9%/yr. Reported net income was 77.5B KRW in FY2025, compounding +16.1%/yr from FY2021.
Key figures
Market cap 855B KRW (≈ $628M) · P/S ratio 1.05 · Dividend yield 0.8% · Net margin 4.6% · Return on equity 14.5% · Return on assets (EBIT) 9.5% · Operating margin 3.2% · Revenue (TTM) 860B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 54%, 185750 screens cheaper than that median.
Fair Value models
Bear 75,002 KRWFair Value 100,003 KRWBull 125,004 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.4%
Dividend (yield on the price)0.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 5%
Compare Chong Kun Dang Pharmaceutical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Chong Kun Dang Pharmaceutical Fair Value". https://www.fairvalue-calculator.com/stock/185750
Frequently asked questions
Is Chong Kun Dang Pharmaceutical (185750) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 100,003 KRW versus a price of 64,900 KRW, about +54% upside (undervalued).
What is the fair value of 185750?
Our model-based fair value for Chong Kun Dang Pharmaceutical is 100,003 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 64,900 KRW.
What is the quality score of 185750?
Chong Kun Dang Pharmaceutical has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chong Kun Dang Pharmaceutical (185750)?
Our model-based price target is the fair value of 100,003 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 75,002 KRW, optimistic scenario 125,004 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Chong Kun Dang Pharmaceutical stock forecast for 2026?
Our models put fair value at 100,003 KRW, about +54% upside versus a price of 64,900 KRW (undervalued). Cautious scenario 75,002 KRW, optimistic scenario 125,004 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Chong Kun Dang Pharmaceutical (185750)?
Chong Kun Dang Pharmaceutical reported trailing-twelve-month revenue of about 860B KRW (latest available figure, as of Sep 24, 2026).
Does Chong Kun Dang Pharmaceutical pay a dividend?
Chong Kun Dang Pharmaceutical currently shows a dividend yield of about 0.77% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Chong Kun Dang Pharmaceutical (185750)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chong Kun Dang Pharmaceutical it is 100,003 KRW per share (as of Sep 24, 2026), against a price of 64,900 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Chong Kun Dang Pharmaceutical stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 185750 trades below its calculated fair value: price 64,900 KRW, fair value 100,003 KRW, a gap of about +54% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 185750?
No. The price is what the market pays today (64,900 KRW); the fair value is what the company's own numbers justify (100,003 KRW). For Chong Kun Dang Pharmaceutical the two are 35,103 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Chong Kun Dang Pharmaceutical worth?
The market values Chong Kun Dang Pharmaceutical at about 855B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 64,900 KRW; our models calculate a fair value of 100,003 KRW per share.
What do the bullish and bearish scenarios say about 185750?
Our models span a range for Chong Kun Dang Pharmaceutical: cautious scenario 75,002 KRW, base 100,003 KRW, optimistic 125,004 KRW per share (as of Sep 24, 2026, price 64,900 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Chong Kun Dang Pharmaceutical (185750)?
Balance-sheet figures for Chong Kun Dang Pharmaceutical (as of Sep 24, 2026): return on equity 14.5%, debt of 0.19 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 185750 from its 52-week high?
Chong Kun Dang Pharmaceutical trades at 64,900 KRW, about 34% below its 52-week high of 97,700 KRW and 2% above the low of 63,800 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 100,003 KRW is for.
Which stocks are comparable to Chong Kun Dang Pharmaceutical?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chong Kun Dang Pharmaceutical stock attractive at the current price?
The data as of Sep 24, 2026: price 64,900 KRW, calculated fair value 100,003 KRW (+54%), Quality Score 37/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 185750 calculated?
We run Chong Kun Dang Pharmaceutical through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 100,003 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Chong Kun Dang Pharmaceutical currently trades 54 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chong Kun Dang Pharmaceutical (185750)?
The closing price on Sep 23, 2026 was 64,900 KRW. Our model-based fair value is 100,003 KRW, about +54% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chong Kun Dang Pharmaceutical right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (75,002 KRW). The market is more pessimistic than our downside scenario.
Key figures of Chong Kun Dang Pharmaceutical
How large is the market capitalisation of Chong Kun Dang Pharmaceutical (185750)?
The market capitalisation of Chong Kun Dang Pharmaceutical is 855B KRW (≈ $628M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chong Kun Dang Pharmaceutical (185750)?
The price-to-sales ratio of Chong Kun Dang Pharmaceutical is 1.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Chong Kun Dang Pharmaceutical (185750)?
The dividend yield of Chong Kun Dang Pharmaceutical is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chong Kun Dang Pharmaceutical (185750)?
The net margin of Chong Kun Dang Pharmaceutical is 4.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chong Kun Dang Pharmaceutical (185750)?
The return on equity (ROE) of Chong Kun Dang Pharmaceutical is 14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chong Kun Dang Pharmaceutical (185750)?
On an EBIT basis the return on assets of Chong Kun Dang Pharmaceutical is 9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chong Kun Dang Pharmaceutical (185750)?
The operating margin of Chong Kun Dang Pharmaceutical is 3.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chong Kun Dang Pharmaceutical (185750)?
Revenue at Chong Kun Dang Pharmaceutical is growing +11.7% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chong Kun Dang Pharmaceutical (185750)?
Earnings per share at Chong Kun Dang Pharmaceutical are growing +8.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Chong Kun Dang Pharmaceutical (185750) generate?
The free cash flow of Chong Kun Dang Pharmaceutical is −112B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Chong Kun Dang Pharmaceutical (185750) carry?
The net debt of Chong Kun Dang Pharmaceutical is 142B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Chong Kun Dang Pharmaceutical in the live analysis
One click puts Chong Kun Dang Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
